BERLIN and SEATTLE, March 31, 2008 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX) (Prime Standard:ECX), a cancer molecular diagnostics company developing tests based on DNA methylation, today reported its financial results for the fiscal year ending December 31, 2007 and provided an update on strategy and operations.
